You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK – Agilent Technologies announced on Monday it has received approval from the US Food and Drug Administration for its PD-L1 IHC 28-8 pharmDx as a companion diagnostic for expanded use in non-small cell lung cancer (NSCLC).
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.
As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.